StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.65+0.06 (+1.67%)

Close on Nov 17, 2026Market cap $362.98MP/E –Yield –

ARS Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

ARS Pharmaceuticals's pe ratio was 171.1× on Apr 30, 2025.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 2025171.1×+160.5
2023Jan 31, 202310.6×−2.6
2022Dec 30, 202213.1×–

More ARS Pharmaceuticals figures

See a number that looks wrong?